From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD74
CAS Registry Number 899796-83-9 N
ATC code None
KEGG D08944 YesY
Chemical data
Formula C6518H10066N1758O2020S40
Molecular mass 146.7 kDa
 N (what is this?)  (verify)

Milatuzumab is an anti-CD74[1] humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.[2][3][4][5]

The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.


CD74 is present on a variety of hematological tumors and even on some solid cancers. It is that it is present in limited amounts in normal tissues but widely found in leukemias, lymphomas and the vast majority of multiple myeloma cases. CD74 is involved in a cell-to-cell communication pathway that is critical for survival. When CD74 is blocked by milatuzumab, it can lead to cell death.

In preclinical studies with human lymphomas and myelomas, both naked Milatuzumab and the Milatuzumab conjugated with doxorubicin,[6] an antibody-drug conjugate or ADC, have demonstrated anti-lymphoma activity in-vivo.

CD74 is an attractive target for a drug conjugate because of its rapid internalizing property.

Antibody-drug Conjugates[edit]

Milatuzumab has been linked to doxorubicin to form an antibody-drug conjugate or ADC (know as hLL1-Dox) for treatment of relapsed multiple myeloma. A phase I/II clinical trial has started.[7][8] This open-label, multi-center Phase I/II study aims to evaluate the safety and tolerability of milatuzumab-doxorubicin conjugate in patients with recurrent or refractory multiple myeloma, and to obtain preliminary information on efficacy, pharmacokinetics, and immunogenicity. The ADC will be administered intravenously on days 1, 4, 8, & 11 every 21 days for up to 8 treatment cycles. Four different dose levels of the doxorubicin conjugate of milatuzumab will be studied in groups of 3-6 patients. Once an optimal dose has been found, up to an additional 30 patients will be studied at that dose level.[9]

Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA).


  1. ^ CD74: a new candidate target for the immunotherapy of B-cell neoplasms. R. Stein, M.J. Mattes, T.M. Cardillo, H.J. Hansen, C.H. Chang, J. Burton, S. Govindan, D.M. Goldenberg. Clin Cancer Res 13:5556s-5563s, 2007.
  2. ^ Combination anti-CD74 (Milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. L. Alinari, B. Yu, B.A. Christian, F. Yan, J. Shin, R. Lapalombella, E. Hertlein, M.E. Lustberg, C. Quinion, X. Zhang, G. Lozanski, N. Muthusamy, M. Praetorius-Ibba, O.A. O'Connor, D.M. Goldenberg, J.C. Byrd, K.A. Blum, R.A. Baiocchi. Blood 117:4530-4541, 2011.
  3. ^ A Phase I study of Milatuzumab, a humanized anti-CD74 antibody, and Veltuzumab, a humanized anti-CD20 antibody, in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. B. Christian, L. Alinari, C.T. Earl, E. Wilding, C. Quinion, M. Lustberg, D.M. Benson, Jr., J.A. Jones, J.C. Byrd, W.A. Wegener, D.M. Goldenberg, R.A. Baiocchi, K.A. Blum. Blood 116:Abstract 2788, 2010.
  4. ^ TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. I. Binsky, F. Lantner, V. Grabovsky, N. Harpaz, L. Shvidel, A. Berrebi, D.M. Goldenberg, L. Leng, R. Bucala, R. Alon, M. Haran, I. Shachar. J Immunol 184:4761-4769, 2010.
  5. ^ Dose-escalation trial of Milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma. J.L. Kaufman, R. Niesvizky, E.A. Stadtmauer, A. Chanan-Khan, D. Siegel, H. Horne, N. Teoh, W. A. Wegener, D. M. Goldenberg. J Clin Oncol 27:15s (suppl; abstr 8593), 2009.
  6. ^ Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. P. Sapra, R. Stein, J. Pickett, Z. Qu, S.V. Govindan, T.M. Cardillo, H.J. Hansen, I.D. Horak, G.L. Griffiths, D.M. Goldenberg. Clin Cancer Res 11:5257-5264, 2005.
  7. ^ Milatuzumab-Doxorubicin (IMMU-110 / hLL1-dox) Clinical Trials - ADC Review / Journal of Antibody-drug Conjugates [1]
  8. ^ Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma - News Medical and Immunomedics Press Release [2] |date=16 June 2010
  9. ^ A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma. Clinical Trials [3]